Imunon (NASDAQ:IMNN – Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.36) per share for the quarter.
Imunon Stock Down 3.6 %
Shares of Imunon stock opened at $0.83 on Wednesday. The company has a market cap of $12.05 million, a PE ratio of -0.44 and a beta of 2.03. Imunon has a 52 week low of $0.57 and a 52 week high of $3.65. The business has a 50 day moving average price of $0.90 and a 200-day moving average price of $0.95.
Analyst Upgrades and Downgrades
A number of brokerages recently commented on IMNN. D. Boral Capital reaffirmed a “buy” rating and set a $29.00 price target on shares of Imunon in a research report on Wednesday, February 19th. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Imunon in a research report on Thursday, December 19th.
Imunon Company Profile
Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.
Featured Stories
- Five stocks we like better than Imunon
- Roth IRA Calculator: Calculate Your Potential Returns
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
- How to Short Nasdaq: An Easy-to-Follow Guide
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- Upcoming IPO Stock Lockup Period, Explained
- Palantir Stock Nears Bear Market Territory – Why and What’s Next?
Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with MarketBeat.com's FREE daily email newsletter.
